Regulatory FDA weighs drug repurposing pathway for underserved diseases Pharmaceutical TechnologyApproved drugs could be expanded into disease areas with limited commercial potential, providing supporting data is available.Read full story pharminent May 12, 2026 (Last updated: May 16, 2026) Pharmaceutical Technology Approved drugs could be expanded into disease areas with limited commercial potential, providing supporting data is available. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunitiesNext: A year after Vertex’s big launch, pain drug research faces a pivotal moment Related Stories Regulatory Japan approves Sanofi’s Sarclisa combo for MM treatment pharminent June 22, 2026 Regulatory FDA experts endorse Moderna’s mRNA seasonal flu shot pharminent June 19, 2026 Regulatory Moderna flu vaccine wins unanimous support from FDA panel pharminent June 18, 2026
